
TVM Capital restructures; hires Schuler
TVM Capital has reorganised its life science investment practice. In the future, the firm will operate two dedicated teams with differentiated investment concepts to invest in pharmaceutical, biopharmaceutical, medical technologies (medtech) and healthcare services companies. The divisions will be called Healthcare Private Equity and Life Science Venture Capital.
Latest News
Verdane scores 5x MOIC in partial exit of Inriver to THL
Majority investment from THL Partners sees Verdane retain a minority stake in the Swedish company
CVC to buy sports nutrition specialist The Quality Group
GP to acquire majority stake via Fund VIII; German group’s founders to reinvest in the deal
DBAG to target EUR 1.3bn-EUR 1.5bn for new buyout fund next year
German GP’s new vehicle will be slightly larger than its predecessor, which is set to complete deployment in two years
Alcedo heads for June final close for Fund V
Italian GP has received EUR 230m in commitments to date for Fund V against a EUR 250m hard-cap